An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy and Safety of Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
Latest Information Update: 19 May 2025
At a glance
- Drugs Rituximab (Primary) ; Sonrotoclax (Primary) ; Zanubrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 11 May 2025 Status changed from not yet recruiting to recruiting.
- 19 Jun 2024 New trial record